FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:823 September 12, 1996 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Braunstein, G. D. PubMed Citation

To the Editor: From June 1992, when finasteride (Proscar) was approved for the treatment of prostatic hyperplasia, to February 1995, the Food and Drug Administration (FDA) received reports of gynecomastia in 214 men (ages, 47 to 90 years; median, 71) in the United States who were taking the drug. Gynecomastia has been the most frequently reported adverse effect of this drug, with an onset ranging from 14 days to 2 1/2 years (median, 180 days) after the initiation of therapy. Most of the men were taking the recommended daily dose of 5 mg. About 30 percent had unilateral gynecomastia, and . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wysowski, D. K., Swartz, L. (2005). Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions. Arch Intern Med 165: 1363-1369 [Abstract] [Full Text]